Careseng 1370 for Chemotherapy-Induced Myelosuppression
Status:
Withdrawn
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/IIa dose-finding (Phase I) followed by randomized, double-blind,
placebo-controlled, parallel, add-on to cisplatin + docetaxel (Phase IIa) study to evaluate
the safety, tolerability, and efficacy profiles of Careseng 1370 in subjects with advanced
NSCLC.